Regulatory T cells, interleukin (IL)-6, IL-8, Vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma

BJU International

Volumn 112, Issue 5, 2013, Pages 686-696

  Polimeno, Marianeve ^a   Napolitano, Maria ^a   Costantini, Susan ^a   Portella, Luigi ^a   Esposito, Arianna ^a   Capone, Francesca ^a   Guerriero, Eliana ^a   Trotta, Annamaria ^a   Zanotta, Serena ^a   Pucci, Luigi ^b   Longo, Nicola ^b   Perdonà, Sisto ^a   Pignata, Sandro ^a   Castello, Giuseppe ^a   Scala, Stefania ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

chemokine; cytokine; growth factors; NK; renal cell carcinoma; Treg

Indexed keywords

CD16 ANTIGEN; CD161 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD45RA ANTIGEN; CD45RO ANTIGEN; CXCL11 CHEMOKINE; EPIDERMAL GROWTH FACTOR; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL1; SCATTER FACTOR; TRANSCRIPTION FACTOR FOXP3; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; NATURAL KILLER T CELL; NEPHRECTOMY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TH1 CELL; TH2 CELL;

CHEMOKINE; CYTOKINE; GROWTH FACTORS; NK; RENAL CELL CARCINOMA; TREG;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARCINOMA, RENAL CELL; CD4-POSITIVE T-LYMPHOCYTES; CHEMOKINE CXCL10; CHEMOKINE CXCL11; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; EPIDERMAL GROWTH FACTOR; FEMALE; FLOW CYTOMETRY; HEPATOCYTE GROWTH FACTOR; HUMANS; IMMUNOPHENOTYPING; INTERLEUKIN-6; INTERLEUKIN-8; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; T-LYMPHOCYTES, REGULATORY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84882248062     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12068     Document Type: Article

References (46)

1. Feng L, Wang X,. Targeting Foxp3+ regulatory T cells-related immunosuppression for cancer immunotherapy. Chin Med J 2010; 123: 3334-3342
2. Wilczynski JR, Kalinka J, Radwan M,. The role of the T-regulatory cells in pregnancy and cancer. Front Biosci 2008; 13: 2275-2289
3. Volpe A, Patard JJ,. Prognostic factors in renal cell carcinoma. World J Urol 2010; 28: 319-327
4. Fuhrman SA, Lasky LC, Limas C,. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6: 655-663
5. Bromwich EJ, McArdie PA, Canna K,. The relationship between T-lymphocyte infiltration, stage, tumor grade and survival in patients undergoing curative surgery for renal cell cancer. Br J Cancer 2003; 89: 1906-1908
6. Kruck S, Kuczyk MA, Gakis G, Kramer MW, Stenzl A, Merseburger AS,. Novel therapeutic options in metastatic renal cancer-review and post ASCO 2007 update. Rev Recent Clin Trials 2008; 3: 212-216.
7. Dutcher J,. Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma. Oncology 2002; 16: 4-10
8. Donskov F,. Interleukin-2 based immunotherapy in patients with metastatic renal cell carcinoma. Dan Med Bull 2007; 54: 249-265
9. Nishikawa H, Kato T, Tawara I, et al. Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts. Proc Natl Acad Sci U S A 2005; 102: 9253-9257
10. Liotta F, Gacci M, Frosali F, et al. Frequency of regulatory T cells in peripheral blood and in tumour-infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma. BJU Int 2011; 107: 1500-1506
11. Sakaguchi S, Yamaguchi T, Nomura T, Ono M,. Regulatory T cells and immune tolerance. Cell 2008; 133: 775-787
12. Sakaguchi S, Miyara M, Costantino CM, Hafler DA,. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010; 10: 490-500
13. Elkord E, Sharma S, Burt DJ, Hawkins RE,. Expanded subpopulation of FoxP3+ T regulatory cells in renal cell carcinoma co-express Helios, indicating they could be derived from natural but not induced Tregs. Clin Immunol 2011; 140: 218-222
14. Attig S, Hennenlotter J, Pawelec G, et al. Simultaneous Infiltration of Polyfunctional Effector and Suppressor T Cells into Renal Cell Carcinomas. Cancer Res 2009; 69: 8412-8419
15. Capone F, Costantini S, Guerriero E, et al. Serum cytokine levels in patients with hepatocellular carcinoma. Eur Cytokine Netw 2010; 21: 99-104
16. Costantini S, Capone F, Guerriero E, et al. Serum cytokine levels as putative prognostic markers in the progression of chronic HCV hepatitis to cirrhosis. Eur Cytokine Netw 2010; 21: 251-256
17. Bellastella G, Rotondi M, Pane E, et al. Simultaneous evaluation of the circulating levels of both Th1 and Th2 chemokines in patients with autoimmune Addison's disease. J Endocrinol Invest 2011; 34: 831-834
18. Xia J, Wishart DS,. MetPA: a web-based metabolomics tool for pathway analysis and visualization. Bioinformatics 2010; 26: 2342-2344
19. Thomas S, Bonchev D,. A survey of element software for network analysis in molecular biology. Hum Genomics 2010; 4: 353-360
20. Porta C, Paglino C, Imarisio I, et al. Changes in Circulating Pro-Angiogenic Cytokines, other than VEGF, before Progression to Sunitinib Therapy in Advanced Renal Cell Carcinoma Patients. Oncology 2012; 84: 115-122
21. Kastritis E, Charidimou A, Varkaris A, Dimopoulos MA,. Targeted therapies in multiple myeloma. Target Oncol 2009; 4: 23-36
22. Adachi Y, Yoshio-Hoshino N, Nishimoto N,. The blockade of IL-6 signaling in rational drug design. Curr Pharm Des 2008; 14: 1217-1224
23. Guo Y, Xu F, Lu T, Duan Z, Zhang Z,. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 2012; 38: 904-910
24. Fitzgerald JP, Nayak B, Shanmugasundaram K, et al. Nox4 mediates renal cell carcinoma cell invasion through hypoxia-induced interleukin 6- and 8- production. PLoS ONE 2012; 7: e30712
25. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-949
26. Hiraoka N, Onozato K, Kosuge T, Hirohashi S,. Prelavence of Foxp3+ regulatory cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 2006; 12: 5423-5434
27. Fu J, Xu D, Liu Z, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007; 132: 2328-2339
28. Griffiths RW, Elkord E, Gilham DE, et al. Frequency of regulatory T cells in renal cell carcinom patinets and investigation of correlation with survival. Cancer Immunol Immunother 2007; 56: 1743-1753
29. Li JF, Chu YW, Wang GM, et al. The prognostic value of peritumoral regulatory T cells and its correlation with intratumoral cyclooxygenase-2 expression in clear cell renal cell carcinoma. BJU INT 2009; 103: 399-405
30. Siddiqui SA, Frigola X, Bonne-Annee S, et al. Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma. Clin Cancer Res 2007; 13: 2075-2081
31. Oldham KA, Parsonage G, Bhatt RI, et al. T lymphocyte recruitment into renal cell carcinoma tissue: a role for chemokine receptors CXCR3, CXCR6, CCR5, and CCR6. Eur Urol 2012; 61: 385-394
32. Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K,. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 2000; 356: 1795-1799
33. Carrega P, Morandi B, Costa R, et al. Natural killer cells infiltration human nonsmall-cell lung cancer are enriched in CD56brightCD16- cells and display an impaired capability to kill tumor cells. Cancer 2008; 112: 863-875
34. Platonova S, Cherfils-Vicini J, Damotte D, et al. Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer 2011; 71: 5412-5422
35. Esendagli G, Bruderek K, Goldmann T, et al. Malignant and non-malignant lung tissue areas are differentially populated by natural killer cells and regulatory T cells in non-small cell lung cancer. Lung Cancer 2008; 59: 32-40
36. Eckl J, Buchner A, Prinz PU, et al. Trascript signature predicts tissue NK cell content and defines renal cell carcinoma subgroups independent of TNM staging. J Mol Med 2011; 90: 55-66
37. Ménard C, Blay JY, Borg C, et al. Natural killer cell IFN-g levels predict long-term serviva with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Res 2009; 69: 3563-3569
38. Albertsson PA, Basse PH, Hokland M, et al. NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity. Trends Immunol 2003; 24: 603-609
39. Konjevic G, Martinovic K, Jurisic V, Babovic N, Spuzic I,. Biomarkers of suppressed natural killer (NK) cell function in metastatic melanoma: decreased NKG2D and increased CD158a receptors on CD3-CD16+ NK cells. Biomarkers 2009; 14: 258-270
40. Foster K, Prowse A, van den, Berg A, et al. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum Mol Genet 1994; 3: 2169-2173
41. Perier A, Fregni G, Wittnebel S, et al. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma. Oncogene 2011; 30: 2622-2632
42. Kanzler I, Tuchscheerer N, Steffens G, et al. Differential roles of angiogenic chemokines in endothelial progenitor cell-induced angiogenesis. Basic Res Cardiol 2013; 108: 310
43. Jacobsen J, Grankvist K, Rasmuson T, et al. Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int 2004; 93: 297-302
44. Tran HT, Liu Y, Zurita AJ, et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol 2012; 13: 827-837
45. Morais C, Pat B, Gobe G, Johnson DW, Healy H,. Pyrrolidine dithiocarbamate exerts anti-proliferative and pro-apoptotic effects in renal cell carcinoma cell lines. Nephrol Dial Transplant 2006; 21: 3377-3388
46. Kondo T, Nakazawa H, Ito F, et al. Favorable prognosis of renal cell carcinoma with increased expression of chemokines associated with a Th1-type immune response. Cancer Sci 2006; 97: 780-786